Karen E Lamb1, Stefan Flasche2, Mathew Diggle3, Donald Inverarity4, David Greenhalgh5, Johanna M Jefferies6, Andrew Smith7, Giles F S Edwards8, Barbara Denham8, Jim McMenamin9, Eisin McDonald9, Tim J Mitchell10, Stuart C Clarke11, Chris Robertson12. 1. Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, United Kingdom; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Road, Parkville, VIC, Australia. Electronic address: karen.lamb@mcri.edu.au. 2. Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, United Kingdom; Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, 61 Colindale Avenue, London, United Kingdom. 3. Molecular Diagnostics East Midlands Pathology Clinical Microbiology Department, Queens Medical Centre, Nottingham, United Kingdom. 4. Department of Microbiology, Monklands Hospital, Monkscourt Avenue, Airdrie, United Kingdom. 5. Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, United Kingdom. 6. Molecular Microbiology Group, Sir Henry Wellcome Laboratories, Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, United Kingdom. 7. Infection and Immunity Research Group, Glasgow Dental School, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom. 8. Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory, Stobhill General Hospital, Glasgow, United Kingdom. 9. Health Protection Scotland, Glasgow, United Kingdom. 10. Institute of Microbiology and Infection, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom. 11. Molecular Microbiology Group, Sir Henry Wellcome Laboratories, Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Health Protection Agency, Southampton, United Kingdom; Southampton NIHR Respiratory Biomedical Research Unit, University Hospital Southampton Foundation NHS Trust, Southampton, United Kingdom. 12. Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, United Kingdom; Health Protection Scotland, Glasgow, United Kingdom. Electronic address: chris.robertson@strath.ac.uk.
Abstract
INTRODUCTION: The 7-valent pneumococcal conjugate vaccine (Prevenar(®), Wyeth; PCV7) was introduced to the UK paediatric immunisation schedule in 2006. This study investigates trends in serotypes and multi locus sequence types (STs) among cases of invasive pneumococcal disease (IPD) in Scotland prior to, and following, the introduction of PCV7. METHODS: Scottish Invasive Pneumococcal Disease Enhanced Surveillance has records of all cases of IPD in Scotland since 1999. Cases diagnosed from blood or cerebrospinal fluid isolates until 2010 were analysed. Logistic and poisson regression modelling was used to assess trends prior to and following the introduction of PCV7. RESULTS: Prior to PCV7 use, on average 650 cases of IPD were reported each year; 12% occurred in those aged <5 years and 35% affected those aged over 65 years. Serotypes in PCV7 represented 47% of cases (68% in <5 year olds). The serotype and ST distribution was relatively stable with only serotype 1 and associated ST 306 showing an increasing trend. PCV7 introduction was associated with a 69% (95% CI: 50%, 80%) reduction in the incidence of IPD among those aged <5 years, a 57% (95% CI: 47%, 66%) reduction among those aged 5-64 years but no significant change among those aged 65 years and over where increases in non-PCV7 serotypes were observed. Serotypes which became more prevalent post-PCV7 are those which were associated with STs related to the PCV7 serotypes. CONCLUSIONS: Routine serotyping and sequence typing in Scotland allowed the assessment of the relationship between the capsule and the clones in the post vaccination era. Changes in the distribution of serotypes post PCV7 introduction appear to be driven by associations between serotypes and STs prior to PCV7 introduction. This has implications for the possible effects of the introduction of higher valency vaccines and could aid in predicting replacement serotypes in IPD.
INTRODUCTION: The 7-valent pneumococcal conjugate vaccine (Prevenar(®), Wyeth; PCV7) was introduced to the UK paediatric immunisation schedule in 2006. This study investigates trends in serotypes and multi locus sequence types (STs) among cases of invasive pneumococcal disease (IPD) in Scotland prior to, and following, the introduction of PCV7. METHODS: Scottish Invasive Pneumococcal Disease Enhanced Surveillance has records of all cases of IPD in Scotland since 1999. Cases diagnosed from blood or cerebrospinal fluid isolates until 2010 were analysed. Logistic and poisson regression modelling was used to assess trends prior to and following the introduction of PCV7. RESULTS: Prior to PCV7 use, on average 650 cases of IPD were reported each year; 12% occurred in those aged <5 years and 35% affected those aged over 65 years. Serotypes in PCV7 represented 47% of cases (68% in <5 year olds). The serotype and ST distribution was relatively stable with only serotype 1 and associated ST 306 showing an increasing trend. PCV7 introduction was associated with a 69% (95% CI: 50%, 80%) reduction in the incidence of IPD among those aged <5 years, a 57% (95% CI: 47%, 66%) reduction among those aged 5-64 years but no significant change among those aged 65 years and over where increases in non-PCV7 serotypes were observed. Serotypes which became more prevalent post-PCV7 are those which were associated with STs related to the PCV7 serotypes. CONCLUSIONS: Routine serotyping and sequence typing in Scotland allowed the assessment of the relationship between the capsule and the clones in the post vaccination era. Changes in the distribution of serotypes post PCV7 introduction appear to be driven by associations between serotypes and STs prior to PCV7 introduction. This has implications for the possible effects of the introduction of higher valency vaccines and could aid in predicting replacement serotypes in IPD.
Authors: Diana Fatykhova; Anne Rabes; Christoph Machnik; Kunchur Guruprasad; Florence Pache; Johanna Berg; Mario Toennies; Torsten T Bauer; Paul Schneider; Maria Schimek; Stephan Eggeling; Timothy J Mitchell; Andrea M Mitchell; Rolf Hilker; Torsten Hain; Norbert Suttorp; Stefan Hippenstiel; Andreas C Hocke; Bastian Opitz Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Ki Wook Yun; Eun Hwa Choi; Hoan Jong Lee; Jin Han Kang; Kyung-Hyo Kim; Dong Soo Kim; Yae-Jean Kim; Byung Wook Eun; Sung Hee Oh; Hye-Kyung Cho; Young Jin Hong; Kwang Nam Kim; Nam Hee Kim; Yun-Kyung Kim; Hyunju Lee; Taekjin Lee; Hwang Min Kim; Eun Young Cho; Chun Soo Kim; Su Eun Park; Chi Eun Oh; Dae Sun Jo; Young Youn Choi; Jina Lee Journal: BMC Infect Dis Date: 2018-06-08 Impact factor: 3.090
Authors: Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore Journal: PLoS Med Date: 2013-09-24 Impact factor: 11.069
Authors: Stefan Flasche; W John Edmunds; Elizabeth Miller; David Goldblatt; Chris Robertson; Yoon Hong Choi Journal: Proc Biol Sci Date: 2013-10-02 Impact factor: 5.349